Skip to content
Catalyst

PapersPMID:20014183

A randomized, controlled, double-blind, pilot study of milk thistle for the treatment of hepatotoxicity in childhood acute lymphoblastic leukemia (ALL).

Cancer2010The record ↗

  1. Finding, moderate evidencelowersAspartate aminotransferase

What moved

1 findingHow to read these marks →
  • “At day 56, the MT group had lower AST than the placebo group (p= 0.04).”
    Study
    RCT
    Duration
    4 weeks
    Dose studied
    silibinin target 5.1 mg/kg/day by weight band (80, 160, 240 or 320 mg/day), by mouth daily for 28 days
    Population
    children aged 1-21 with acute lymphoblastic leukaemia in maintenance chemotherapy with grade 2 or higher hepatic toxicity; AST at day 56, four weeks after the 28-day course ended

Study record

Design
randomised controlled trial
Species
human / mixed
Population
children with acute lymphoblastic leukemia in maintenance therapy with grade 2 or greater hepatic toxicity; plus CCRF-CEM T-cell ALL cells in vitro
Participants
50
Comparator
placebo
Duration
28 days
Endpoints measured
30